Zanubrutinib

Zanubrutinib in the glossary for Waldenström's macroglobulinemia

A small molecule second-generation inhibitor of Bruton's tyrosine kinase

Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Zanubrutinib is approved for the treatment of mantle cell lymphoma (MCL) in ten countries, including China, Canada, Australia and Russia.¹ It is also approved for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in China. ¹ Zanubrutinib is approved in the EU, UK and Australia for the treatment of adult patients with WM who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. ^1,2,3

Glossary overview

References

1.BeiGene Press Release 2022. Available from; https://ir.beigene.com/news-details/?id=6341fab4-f8e5-4375-a36f-3cedef177fc4. Accessed February 8th, 20222.

2.Zanubrutinib SmPC Available from; https://www.ema.europa.eu/en/documents/product-information/brukinsa-epar-product-information_en.pdf. Accessed February 12th, 2022.

3.Australian Public Assessment Report for Zanubrutinib. Available from; https://www.tga.gov.au/apm-summary/brukinsa-0. Accessed February 8th, 2022.

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please consult the appropriate national or regional regulatory authority for specific information on a product or indication included here.